news
NICE recommends avelumab and axitinib to treat renal cell carcinoma
Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
List view / Grid view
Kidney cancer
Filter the results
news
FDA approves first biosimilar for the treatment of cancer
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers…
news
Scotland approves Ipsen’s cabozantinib to treat kidney cancer
The SMC endorses routine prescribing across NHS Scotland of Ipsen’s cabozantinib, offering a new therapy option to help battle kidney cancer.
news
NICE approves former CDF kidney cancer drug for NHS use
12 January 2017 | By Niamh Marriott, Digital Editor
Everolimus (Afinitor, Novartis) is now recommended to be available on the NHS as a treatment option for some patients with advanced renal cell carcinoma...
article
K is for Kidney
28 November 2016 | By Niamh Louise Marriott, Digital Editor
K is for Kidney - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...
news
NICE recommends ‘breakthrough’ drug nivolumab for advanced renal cell cancer
21 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Nivolumab is an intravenous drug, a form of immunotherapy that works by harnessing the power of the patient’s own immune system to destroy the cancer cells...
news
Ipsen’s kidney cancer drug receives positive CHMP and ‘Promising Innovative Medicine’ status
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Ipsen announced that CHMP & EMA have provided a positive opinion for Cabometyx for the treatment of advanced renal cell carcinoma (RCC) in adults...